Compare TKR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKR | TGTX |
|---|---|---|
| Founded | 1899 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.5B |
| IPO Year | 1994 | 2008 |
| Metric | TKR | TGTX |
|---|---|---|
| Price | $131.89 | $49.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $118.29 | $49.80 |
| AVG Volume (30 Days) | 833.4K | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 1.81 | 0.12 |
| Revenue | ★ $80,100,000.00 | $2,785,000.00 |
| Revenue This Year | $4.57 | $49.08 |
| Revenue Next Year | $3.97 | $26.69 |
| P/E Ratio | ★ $94.31 | $406.13 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $70.79 | $25.37 |
| 52 Week High | $146.37 | $59.30 |
| Indicator | TKR | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 41.49 |
| Support Level | $105.06 | $28.57 |
| Resistance Level | $144.78 | $58.08 |
| Average True Range (ATR) | 4.96 | 2.56 |
| MACD | -0.97 | -1.12 |
| Stochastic Oscillator | 32.97 | 31.61 |
The Timken Co designs and manages a portfolio of engineered bearings and industrial motion products, and provides related services. The various products offered by the company include ball bearings, plain bearings, tapered roller bearings, housed bearings, linear guides, telescopic rails, lubrication systems, agricultural conveyor chains, couplings, brakes, seals, etc. These products are offered through brands like Timken, GGB, Philadelphia Gear, Cone Drive, CGI, and Rollon, among others. The company has two reportable segments: Engineered Bearings, which generates the maximum revenue, and Industrial Motion. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Africa (EMEA), Asia-Pacific, and the other regions of the Americas.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.